<DOC>
	<DOC>NCT01486914</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare insulin aspart produced by current process and the NN2000 process.</brief_summary>
	<brief_title>Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Healthy Caucasian Normal findings in medical history and physical examination unless the investigator considers any abnormality to be clinically irrelevant Fasting blood glucose below or equal to 6 mmol/L Body mass index (BMI) 22.027.0 kg/m^2 (both inclusive) Participated in another clinical study with an investigational drug within the last 4 weeks Any condition requiring the regular use of any medication, including herbal remedies, over the counter medicines and vitamins. Occasional paracetamol is acceptable Known or suspected allergy to the trial product or related products Family history of type 2 diabetes</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>